Clinical trial · Interventional
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
18F-FDOPA PET/CT or PET/MRI in Patients With Gliomas
NCT02175745CI-TRIAL-00026510terminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Re-evaluate indication with the referring physicians
Summary
Brief summary (as posted)
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.
Conditions
Conditions (57)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Anaplastic Ependymoma | Adult Anaplastic Ependymoma | ONTOLOGY_EXACT | 0.98 |
| Adult Anaplastic Oligodendroglioma | Adult Anaplastic Oligodendroglioma | ONTOLOGY_EXACT | 0.98 |
| Adult Brain Stem Glioma | Adult Brain Stem Glioma | ONTOLOGY_EXACT | 0.98 |
| Adult Diffuse Astrocytoma | Adult Diffuse Astrocytoma | ONTOLOGY_EXACT | 0.98 |
| Adult Giant Cell Glioblastoma | Adult Giant Cell Glioblastoma | ONTOLOGY_EXACT | 0.98 |
| Adult Glioblastoma | Adult Glioblastoma | ONTOLOGY_EXACT | 0.98 |
| Adult Gliosarcoma | Adult Gliosarcoma | ONTOLOGY_EXACT | 0.98 |
| Adult Mixed Glioma | Adult Mixed Glioma | ONTOLOGY_EXACT | 0.98 |
| Adult Oligodendroglioma | Adult Oligodendroglioma |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-fluoro-dihydroxyphenylalanine | Drug | — | UNRESOLVED |
| Computed tomography (CT) | Procedure | — | UNRESOLVED |
| Magnetic resonance imaging | Procedure | — | UNRESOLVED |
| Positron emission tomography (PET) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (FDOPA-PET/CT or PET/MRI)
- description
- Patients receive 18F-fluoro-dihydroxyphenylalanine (18F-FDOPA) intravenously (IV) and then undergo positron emission tomography / computed tomography (PET/CT) or PET/magnetic resonance imaging (PET/MRI) scans 10 to 30 minutes later.
- interventionNames
- Drug: 18F-fluoro-dihydroxyphenylalanine
- Procedure: Positron emission tomography (PET)
- Procedure: Computed tomography (CT)
- Procedure: Magnetic resonance imaging
Primary outcomes (2)
- measure
- Number of Suspicious Lesions Identified by 18F FDOPA PET
- timeFrame
- Up to 30 minutes after injection of F18 FDOPA
- description
- The number of suspicious lesions will be identified by uptake of F18 FDOPA radiopharmaceutical using a positron emission tomography (PET) scan. Uptake of F-18 FDOPA is a measure of amino acid uptake and metabolism in tumors. Suspicious lesions will be visually identified by a board certified nuclear medicine physician.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * Greater than 15 year-old at the time of radiotracer administration * Provides written informed consent * Suspected new diagnosis or suspected recurrence of glioma * Able to remain still for duration of each imaging procedure (about 20 minutes) Exclusion Criteria: * Less than 15 year-old at the time of radiotracer administra * Unable to provide informed consent * Inability to lie still for the entire imaging time * Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
References
Publications (0)
Data not yet available
No reference posted for this study.